Project Grant R21NS145112
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Van Andel Research Institute a Project Grant of $555,128 under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective March 1, 2026, through January 31, 2031. The grant funds research investigating the mechanisms of gain-of-repeat-toxicity and loss-of-C9ORF72-function in frontotemporal dementia (FTD) and amyotrophic lateral...
- Federal Project Grant Award Summary The University of California, San Diego received a $3,081,936 Project Grant awarded on September 12, 2025, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The grant funds fundamental research to elucidate the mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) through development and application of...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This exploratory research project, scheduled for completion by May 31, 2027, investigates the roles of the deubiquitylation pathway in TDP-43 (TAR DNA-binding protein 43) pathology relevant to...
- Federal Grant Award Summary The University of Pennsylvania received a $3.2 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 1, 2025, with completion targeted for July 31, 2029. This research initiative will identify genetic modifiers contributing to phenotypic heterogeneity in the amyotrophic lateral sclerosis (ALS) and...
- Federal Project Grant Award Summary Pennsylvania State University, operating through Penn State Milton S. Hershey Medical Center, received a $432,802 project grant awarded June 1, 2025, from the National Institute of Neurological Disorders and Stroke under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The two-year award, with completion scheduled for May 31, 2027, supports cross-validation research of gene expression changes associated...
- This Project Grant award of $925,757.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Wake Forest University Health Sciences (WFUHS) for the project "SELECTIVE REDUCTION OF REPEAT EXPANSION RNA WITH SMALL MOLECULES TO TREAT C9ORF72 MEDIATED ALS." The funding supports advanced biomedical research to develop innovative medical solutions that address critical health challenges relevant to military personnel and...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support a two-year research investigation through May 31, 2027. The project, titled "Investigating the Role of TDP-43 Citrullination in ALS Pathogenesis," focuses on understanding how...
- Federal Project Grant Award Summary Case Western Reserve University's Office of Research Administration received a $1,475,440 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective July 1, 2025, through March 31, 2030. The award funds a research investigation titled "Regulation of ATAD3A in TDP43-Associated ALS/FTD" to be...
- Federal Project Grant Award Summary Colorado State University received a $2,674,385 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 15, 2025, with completion targeted for July 31, 2029. This research initiative investigates structure-function relationships in alpha-synuclein protein strains using cryo-electron microscopy (cryo-EM)...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Pennsylvania a Project Grant of $2.7 million under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective September 5, 2025, through August 31, 2029. This research initiative will investigate the role of TRIM11 protein in regulating transactive response DNA-binding protein 43 (TDP-43) and fused-in-sarcoma...
Wake Forest University Health Sciences received a $406,640 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective May 4, 2026, with a completion date of April 30, 2028. The award supports research assessing the outcomes and therapeutic potential of targeted C9ORF72 methylation for treatment of C9FTD/ALS (C9ORF72-related frontotemporal dementia and amyotrophic lateral sclerosis), the major genetic cause of frontotemporal dementia and ALS characterized by a G4C2 repeat expansion in the C9ORF72 gene. The research employs CRISPRoff, a CRISPR-based system utilizing dCas9-methyltransferase fusion technology, to induce targeted DNA methylation of the C9ORF72 promoter and repeat expansion sequence. The therapeutic approach aims to reduce production of harmful repeat-containing RNA transcript variants and their associated poly-dipeptide repeat proteins while preserving expression of the primary C9ORF72 protein-coding transcript. The project addresses a significant gap in neurological disease treatment by developing a non-cleavage-based, transiently deliverable gene-targeted intervention with potential allele-selective activity against the expanded repeat sequence.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $406.6k | 5/5/26 |